About Us Weight Loss TRT Women's HRT Peptide Therapy
Rejuvenation
IV Therapy Laser Hair Removal
Get Started
Book a Consultation Call

MEDICAL WEIGHT LOSS

GLP-1 Medication Comparison

Semaglutide vs. Tirzepatide: Which GLP-1 Medication Is Right for You?

MH
Mathew Hammons
PA-C · Optimized Health
March 23, 2026 10 min read

If you're exploring medical weight loss, you've likely come across both names. Semaglutide and tirzepatide are two of the most widely used GLP-1 medications for weight management — and the clinical data behind both is compelling. But they work through different mechanisms, carry different considerations, and may produce different results depending on your health profile and goals. This guide breaks down the real differences so you can have a more informed conversation with your provider.

What Are GLP-1 Medications — and Why Are They Changing the Conversation?

GLP-1 stands for glucagon-like peptide-1, a hormone your body produces naturally in response to food. It signals your brain that you're full, slows digestion so nutrients absorb more gradually, and helps regulate blood sugar. In many people carrying excess weight, these signaling pathways don't function as effectively — which is one reason lifestyle changes alone often aren't enough.

GLP-1 receptor agonists are injectable medications that mimic and amplify this natural hormone signal. They work alongside your body's existing regulatory systems to support appetite control and metabolic function. The result, when combined with clinician-supervised care, can be clinically significant weight loss that proves difficult to achieve through diet and exercise alone.

Both semaglutide and tirzepatide belong to this broader class, but they aren't identical. Understanding the difference between a single-receptor and dual-receptor approach is the key to understanding which may be more appropriate for your situation.

The Science: How Semaglutide and Tirzepatide Actually Work

Semaglutide: The GLP-1 Receptor Agonist

Semaglutide activates one receptor — GLP-1. It mimics the gut hormone that tells your brain you're full, slows gastric emptying so you feel satisfied longer, suppresses glucagon (which reduces excess sugar production by the liver), and influences appetite-control centers in the brain to reduce cravings.

It's administered as a once-weekly subcutaneous injection. The dosing typically starts low — often at 0.25mg weekly — and is titrated upward over several months toward a target maintenance dose of up to 2.4mg, depending on individual tolerance and clinical response. This gradual approach is designed to minimize gastrointestinal side effects.

Semaglutide has been studied extensively in the STEP clinical trial program. In STEP 1, participants taking 2.4mg weekly achieved an average weight loss of approximately 15–17% of their body weight over 68 weeks. The branded versions — Wegovy (approved for weight management) and Ozempic (approved for type 2 diabetes) — are the FDA-approved formulations of semaglutide.

Tirzepatide: The Dual GLP-1/GIP Receptor Agonist

Tirzepatide activates the same GLP-1 receptor as semaglutide, plus a second receptor — GIP (glucose-dependent insulinotropic polypeptide) — that influences metabolism through an additional pathway. This dual-receptor approach is designed to enhance insulin sensitivity, support fat metabolism, and provide additional appetite suppression through a mechanism semaglutide doesn't reach.

Like semaglutide, tirzepatide is a once-weekly injection. Dosing typically starts at 2.5mg and can be titrated up to a maximum of 15mg, with adjustments made based on individual tolerance and response. The SURMOUNT clinical trial program demonstrated significant results — up to 20–21% average body weight loss at the highest doses over 72 weeks. Head-to-head and comparative analyses between the STEP and SURMOUNT programs suggest tirzepatide produces greater average weight loss than semaglutide at maximum doses. The branded versions — Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes) — are the FDA-approved formulations of tirzepatide.

These findings are drawn from large randomized controlled trial programs — STEP for semaglutide and SURMOUNT for tirzepatide — which represent the most comprehensive clinical evidence available for GLP-1 medications in weight management.

Side-by-Side: Semaglutide vs. Tirzepatide at a Glance

Category Semaglutide Tirzepatide
Mechanism GLP-1 receptor agonist Dual GLP-1 + GIP receptor agonist
FDA-Approved Brands Wegovy (weight loss), Ozempic (diabetes) Zepbound (weight loss), Mounjaro (diabetes)
Administration Once-weekly injection Once-weekly injection
Typical Starting Dose 0.25mg weekly 2.5mg weekly
Target Maintenance Dose Up to 2.4mg weekly Up to 15mg weekly
Avg. Weight Loss (clinical trials) ~15–17% body weight (STEP program, 68 weeks) ~20–21% body weight (SURMOUNT program, 72 weeks)
Common Side Effects Nausea, vomiting, diarrhea, constipation Nausea, vomiting, diarrhea, constipation
Titration Period ~16–17 weeks to reach max dose ~20–24 weeks to reach max dose
Cost at Optimized Health* From $200/mo From $250/mo

Clinical trial results represent averages from controlled research studies. Individual results vary based on starting weight, adherence, lifestyle factors, and clinical supervision. Results may vary.

*Optimized Health programs use compounded formulations — not the branded products listed above. Compounded medications contain semaglutide or tirzepatide as the active ingredient but are prepared by licensed compounding pharmacies and are not FDA-approved products. Your clinician will discuss the specifics of your prescribed formulation during your consultation.

Safety Considerations You Should Know About

Both semaglutide and tirzepatide have well-documented safety profiles based on large clinical trial programs involving thousands of participants across multiple randomized controlled trials. However, like all prescription medications, they carry risks that your clinician will evaluate before prescribing.

Common side effects

The most frequently reported side effects for both medications are gastrointestinal — nausea, diarrhea, vomiting, and constipation. These are most common during the initial weeks and after each dose increase, and generally improve as the body adjusts. The gradual titration schedule is specifically designed to minimize these effects. Your clinician can adjust the pace of titration based on your individual tolerance.

Serious risks and contraindications

Important Safety Information

Both semaglutide and tirzepatide carry a boxed warning regarding thyroid C-cell tumors. In animal studies, these medications caused thyroid C-cell tumors. It is not known whether they cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Both medications are also contraindicated during pregnancy and should be discontinued at least two months before a planned pregnancy.

Additional serious but uncommon risks include pancreatitis, gallbladder disease, and dehydration-related kidney complications. Patients with a history of pancreatitis should discuss this with their provider before starting either medication. These medications are not appropriate for patients with type 1 diabetes, and caution is warranted for patients with severe gastrointestinal conditions such as gastroparesis.

Why clinician supervision matters

This is precisely why GLP-1 therapy requires ongoing clinical oversight — not a one-time prescription and a "good luck." Your provider monitors for adverse effects, adjusts dosing based on your tolerance, orders lab work to track metabolic changes, and makes clinical decisions that an algorithm or questionnaire cannot replicate.

So Which One Should You Consider?

The honest answer: it depends on your body, your goals, your health history, and your budget. There's no universally "better" medication — there's the one that may be more appropriate for your clinical situation.

Semaglutide may be worth considering if:

You're beginning GLP-1 therapy for the first time and want a well-studied medication with the longest real-world track record in weight management. Semaglutide has been prescribed to millions of patients and has extensive clinical data supporting its safety and efficacy. At Optimized Health, compounded semaglutide programs start at $200/month — making it the more accessible starting point for patients beginning a longer treatment course.

Tirzepatide may be worth discussing if:

You've tried semaglutide and reached a plateau, or you and your clinician determine that the dual-receptor approach may offer additional benefit. Tirzepatide's GLP-1/GIP mechanism has consistently produced greater average weight loss in clinical trials. For patients with concurrent metabolic concerns such as insulin resistance, the additional GIP receptor activation may be a factor worth discussing with your provider. Compounded tirzepatide programs start at $250/month at Optimized Health.

Your clinician makes the final call

Neither medication should be chosen based on a blog article. Your provider evaluates your complete clinical picture — metabolic health, medication history, weight loss goals, potential contraindications, and how your body has responded to previous treatments. At Optimized Health, your protocol is built around your labs, your symptoms, and your goals — not a one-size-fits-all prescription.

Explore our medical weight loss programs →

What to Expect When Starting Either Medication

The first 4–8 weeks

Both medications start at lower doses designed to improve tolerability before reaching therapeutic levels. Many patients begin noticing some appetite changes within the first few weeks, but measurable weight loss typically becomes more apparent as the dose titrates upward over the first one to two months. The timeline varies by individual.

The most common side effects during this period are mild nausea, reduced appetite, and occasional digestive discomfort. These generally improve as your body adjusts, though the pace varies. Your clinician monitors your response and adjusts titration timing based on your individual tolerance — not a fixed calendar.

Months 2–4: Where changes tend to become more noticeable

As you approach therapeutic doses, weight loss tends to become more noticeable and consistent. This is where many patients see the changes that reinforce their commitment — clothes fitting differently, energy improving, lab markers trending in the right direction. Your clinician continues adjusting based on your response.

Month 6 and beyond: Ongoing management

GLP-1 medications are most effective as part of an ongoing clinical relationship, not a short-term fix. Your provider monitors your metabolic markers, adjusts protocols as your body changes, and helps you build the nutritional and lifestyle habits that support long-term results. Research indicates that weight regain is common after discontinuing GLP-1 therapy without sustained clinical support, which is why the ongoing provider relationship matters.

Learn more about semaglutide at Optimized Health →
Learn more about tirzepatide at Optimized Health →

What Does GLP-1 Therapy Actually Cost?

Brand-name GLP-1 medications at retail pharmacies can cost over $1,000/month, and insurance coverage varies significantly. At Optimized Health, we operate as a cash-pay concierge practice using compounded formulations — which allows us to offer transparent, significantly lower pricing.

Compounded semaglutide programs start at $200/month. Compounded tirzepatide programs start at $250/month. Both include clinician-supervised dosing, ongoing monitoring, and direct access to your provider. There are no hidden fees and no contracts — you continue as long as the treatment aligns with your goals. HSA and FSA cards are accepted.

About Compounded Formulations

Our programs use compounded semaglutide and tirzepatide prepared by licensed compounding pharmacies. Compounded medications contain semaglutide or tirzepatide as the active ingredient but are not FDA-approved products. Your clinician will discuss the specifics of compounded versus branded formulations during your consultation.

Schedule your consultation →

Frequently Asked

Your GLP-1 Questions, Answered Directly

What is the difference between semaglutide and tirzepatide?

Semaglutide is a GLP-1 receptor agonist — it activates one hormone receptor to reduce appetite, slow digestion, and regulate blood sugar. Tirzepatide is a dual GLP-1/GIP receptor agonist that activates two hormone receptors simultaneously, providing additional metabolic effects through the GIP pathway. In clinical trials, tirzepatide's dual mechanism produced approximately 20% average body weight loss compared to approximately 14–17% for semaglutide over similar timeframes.

Both are administered as once-weekly injections and require clinician supervision for safe use.

How long does it take to see results on semaglutide or tirzepatide?

Many patients begin noticing appetite changes within the first few weeks of treatment. Measurable weight loss typically becomes more apparent within 4–8 weeks as the medication titrates toward therapeutic doses. Semaglutide reaches its target maintenance dose of up to 2.4mg over approximately 16–17 weeks. Tirzepatide reaches its target maintenance dose of up to 15mg over approximately 20–24 weeks.

Peak results in clinical trials were measured at 68–72 weeks. Individual timelines vary significantly based on starting weight, metabolic factors, dose tolerance, and adherence to the supervised protocol.

Can you switch from semaglutide to tirzepatide?

Yes, switching is common in clinical practice. If a patient plateaus on semaglutide or wants to explore the dual-receptor approach, their clinician can transition them to tirzepatide. The transition strategy — including timing, starting dose, and any washout period — varies based on individual factors and clinician judgment. This is a clinical decision that should always be managed by your provider based on your specific response and tolerance history.

Are GLP-1 medications safe for long-term use?

Semaglutide and tirzepatide have been studied in multi-year clinical trial programs (STEP and SURMOUNT respectively) involving thousands of participants across multiple large randomized controlled trials. Both carry FDA approval with well-documented safety profiles for their branded formulations.

The most common side effects are gastrointestinal — nausea, diarrhea, constipation — and these generally diminish as the body adjusts. Both medications carry a boxed warning related to thyroid C-cell tumors observed in animal studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Additional serious but uncommon risks include pancreatitis and gallbladder complications. Both are contraindicated during pregnancy. Ongoing clinician supervision is essential to monitor for adverse effects and adjust treatment as needed.

How much does GLP-1 therapy cost at Optimized Health in Joplin, MO?

Compounded semaglutide programs start at $200 per month and compounded tirzepatide programs start at $250 per month at Optimized Health in Joplin, Missouri. These are all-inclusive prices covering clinician-supervised dosing, ongoing monitoring, and direct provider access. The clinic operates on a cash-pay model with no insurance billing. HSA and FSA cards are accepted. There are no contracts — patients continue treatment as long as it aligns with their clinical goals.

Note: these programs use compounded formulations prepared by licensed compounding pharmacies, not the branded FDA-approved products.

More Questions

More Questions About GLP-1 Medications

Explore Your Treatment Options

Weight Loss

Semaglutide Programs

Clinician-supervised GLP-1 therapy with compounded semaglutide. From $200/mo with ongoing monitoring and direct provider access.

Learn More Weight Loss

Tirzepatide Programs

Dual-action GLP-1/GIP therapy with compounded tirzepatide. From $250/mo with full clinical support and personalized dosing.

Learn More
MH
About the Author

Mathew Hammons

PA-C · Founder & Lead Clinician, Optimized Health · Joplin, MO

Mathew Hammons, PA-C is the founder and lead clinician at Optimized Health in Joplin, Missouri. With over a decade of clinical experience including obesity medicine, hormone optimization, and peptide therapy, he has treated more than 4,000 patients. Mathew takes a personalized, data-driven approach to every protocol — building treatment plans around each patient's labs, goals, and clinical response.

Meet the full clinical team →

Not sure which medication is right for you?

Your Clinician Will Help You Decide.

Schedule a consultation with Mathew Hammons, PA-C. We'll evaluate your health history, discuss your goals, and recommend the protocol that gives you the best path forward. No obligation. No pressure.

Schedule Your Consultation

Telehealth available in MO, KS, IA, UT, WA  ·  HSA/FSA accepted